One of the world's oldest blood pressure drugs may also halt aggressive brain tumor growth

A Penn-led team revealed hydralazine’s long-mysterious mechanism of action: it binds and inhibits the oxygen-sensing enzyme ADO, stabilizing RGS proteins, reducing intracellular calcium and producing vasodilation—clarifying why the decades-old drug is effective in preeclampsia, a condition tied to 5–15% of maternal deaths globally. In preclinical work the same ADO blockade drove glioblastoma cells into senescence rather than killing them, indicating potential to repurpose hydralazine or develop selective ADO inhibitors as non‑cytotoxic therapies for aggressive brain tumors. The authors advocate chemistry-driven development of tissue‑selective, brain‑penetrant ADO inhibitors—identifying a clear translational opportunity for biotech players and investors—results published in Science Advances.

Analysis

A Penn-led team published in Science Advances (2025, DOI: 10.1126/sciadv.adx7687) identified hydralazine's mechanism as direct inhibition of the oxygen-sensing enzyme 2-aminoethanethiol dioxygenase (ADO). The study shows hydralazine binds ADO’s metal center, stabilizes regulators of G-protein signaling (RGS), lowers intracellular calcium and produces vasodilation—resolving a 70-year mechanistic mystery behind its use, including as a first-line therapy for preeclampsia, a condition implicated in 5%–15% of maternal deaths worldwide.

The team extended the biology to oncology, noting elevated ADO activity in glioblastoma; X-ray crystallography and cell assays demonstrated that ADO blockade by hydralazine drives glioblastoma cells into senescence rather than cytotoxic death, reducing proliferation without inducing inflammation or classical resistance pathways. This provides a mechanistic rationale for repurposing hydralazine or developing ADO inhibitors as non-cytotoxic adjuncts in hypoxic tumors.

Translational opportunity is clear but near-term commercial impact is constrained by preclinical status and pharmacology challenges: blood-brain barrier penetration, tissue selectivity and safety/dosing differences between maternal hypertension and oncology must be resolved through medicinal chemistry and clinical trials. Sentiment is mildly positive but contingent on demonstrable in vivo efficacy and tolerability in clinical studies.

Key Decisions for Investors

• Monitor early-stage and mid-stage biotech programs focused on ADO inhibitors or platforms enabling brain-penetrant small molecules, as they represent the most direct beneficiaries of this mechanistic insight
• Defer material portfolio increases until first-in-human or robust in vivo efficacy readouts are reported given current evidence is preclinical, prioritize small, opportunistic exposure rather than large allocations
• Favor companies with proven CNS delivery technologies or credible medicinal chemistry strategies to achieve tissue selectivity and blood-brain barrier penetration, as these attributes materially de-risk development
• Track partnership, licensing and clinical trial announcements tied to hydralazine repurposing or novel ADO programs as catalysts that could re-rate involved equities